The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1307
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).

DRUGS FOR MS — The current treatments for relapsing forms of MS include interferon beta, glatiramer acetate, mitoxantrone and, more recently, natalizumab.1-3 The development of progressive multi-focal leukoencephalopathy (PML) in several patients treated with natalizumab has led some clinicians to reserve it for patients who either do not tolerate or do not respond to interferon beta or glatiramer acetate. Rituximab (Rituxan) has also been tried off-label for this indication.4

MECHANISM OF ACTION — Alemtuzumab binds CD52, an antigen present ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
Article code: 1307a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian